People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Emulate, Inc. | — | Biotechnology | Series C | $182.3M | $1.5B | 2020 |
| Quanterix Corp | — | Other Technology | Series C | $71.8M | $194.1M | 2011 |
| Syntis Bio, Inc. | — | Biotechnology | Series B | $46.7M | $117.9M | 2024 |
Martin Madaus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin Madaus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| John Connolly | 1 | 14 |
| Paul Meister | 1 | 12 |
| Keith Crandell | 1 | 11 |
| ERIC MOESSINGER | 1 | 6 |
| Carlo Giovanni Traverso | 1 | 6 |
| John M. Connolly | 1 | 6 |
| David Walt | 1 | 6 |
| David R. Walt | 1 | 5 |
| Teymour Boutros-Ghali | 1 | 5 |
| Douglas Cole | 1 | 5 |
| Marijn Dekkers | 1 | 4 |
| PAUL M MEISTER | 1 | 4 |
| David Okrongly | 1 | 4 |
| Aaron VanDevender | 1 | 3 |
| Keith L. Crandell | 1 | 3 |
| James Corbett | 1 | 3 |
| Paul Chapman | 1 | 3 |
| Michael Nannizzi | 1 | 3 |
| Donald Ingber | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.